Eiger BioPharmaceuticals, Inc.
EIGRQ · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $15,773 | $13,484 | $12,142 | $0 |
| % Growth | 17% | 11.1% | – | – |
| Cost of Goods Sold | $774 | $2,679 | $1,544 | $645 |
| Gross Profit | $14,999 | $10,805 | $10,598 | -$645 |
| % Margin | 95.1% | 80.1% | 87.3% | – |
| R&D Expenses | $62,331 | $75,282 | $64,436 | $41,590 |
| G&A Expenses | $0 | $0 | $0 | $20,559 |
| SG&A Expenses | $24,454 | $28,263 | $23,101 | $19,914 |
| Sales & Mktg Exp. | $0 | $0 | $0 | -$645 |
| Other Operating Expenses | $87 | -$963 | $0 | -$12 |
| Operating Expenses | $86,785 | $103,545 | $87,537 | $61,504 |
| Operating Income | -$71,786 | -$92,740 | -$76,939 | -$62,149 |
| % Margin | -455.1% | -687.8% | -633.7% | – |
| Other Income/Exp. Net | -$3,171 | -$4,013 | $43,086 | -$2,902 |
| Pre-Tax Income | -$74,957 | -$96,753 | -$33,853 | -$65,051 |
| Tax Expense | $6 | $23 | $64 | $0 |
| Net Income | -$74,963 | -$96,776 | -$33,917 | -$65,051 |
| % Margin | -475.3% | -717.7% | -279.3% | – |
| EPS | -50.78 | -69.74 | -29.98 | -69.34 |
| % Growth | 27.2% | -132.6% | 56.8% | – |
| EPS Diluted | -50.78 | -69.74 | -29.98 | -69.34 |
| Weighted Avg Shares Out | 1,476 | 1,388 | 1,131 | 938 |
| Weighted Avg Shares Out Dil | 1,476 | 1,388 | 1,131 | 938 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,208 | $1,082 | $158 | $704 |
| Interest Expense | $5,466 | $4,132 | $3,559 | $3,594 |
| Depreciation & Amortization | $750 | $842 | $799 | $645 |
| EBITDA | -$68,741 | -$91,898 | -$29,495 | -$61,504 |
| % Margin | -435.8% | -681.5% | -242.9% | – |